In addition, a 1.39-fold increased risk for CHD was observed for every 1 SD decrease of plasma fibronectin and an optimized pFN cut-off value of 183 mg/L could predict CHD, indicating that pFN may be used as a screening marker for CHD in clinical practice when it is below 183 mg/L. The gene discussed is FN1; the disease is coronary artery disorder.